CardioDx Says $58M Financing Will Support Commercial Expansion Following Medicare Coverage Win | GenomeWeb

CardioDx this week completed a $58 million private equity financing round that it will use to support sales of its Corus CAD test and the development of additional diagnostics.

The company said the money will also help support ongoing clinical utility and cost-effectiveness research that it hopes will help persuade private payors to join Medicare contractor Palmetto GBA in covering its coronary artery disease test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.